Merck (MRK)
145.16
+1.23 (0.85%)
Upcoming Events
Latest Headlines
Perspective Therapeutics and Merck to test cancer drug combination
September 14, 2026 6:16 AM - StreetInsider
Perspective Therapeutics Announces Clinical Collaboration and Supply Agreement with Merck to Evaluate [212Pb]PSV359 in Combination with Keytruda® (Pembrolizumab) in FAP-α Positive Solid Tumors
September 14, 2026 6:16 AM - StreetInsider
Merck (MRK) PT Raised to $137 at Berenberg
September 11, 2026 2:44 AM - StreetInsider
Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market
September 10, 2026 8:30 AM - StreetInsider
Merck (MRK) PT Raised to $172 at HSBC
September 10, 2026 3:28 AM - StreetInsider
FDA set to permanently fill top drug, vaccine, and tobacco roles - Bloomberg
September 8, 2026 4:10 PM - StreetInsider
Merck (MRK) PT Raised to $170 at Guggenheim
September 8, 2026 7:16 AM - StreetInsider
Merck to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
September 8, 2026 6:45 AM - BizWire
Merck (MRK) PT Raised to $170 at Wells Fargo
September 4, 2026 6:49 AM - StreetInsider
Merck to Participate in the Wells Fargo 21st Annual Healthcare Conference
September 2, 2026 6:45 AM - BizWire
Form 3 Merck & Co., Inc. For: Sep 01 Filed by: Gupta Gaurav K
September 1, 2026 3:41 PM - SEC Filing
Merck (MRK) PT Raised to $180 at Wolfe Research
August 25, 2026 5:35 AM - StreetInsider
Merck (MRK) PT Raised to $160 at Goldman Sachs
August 21, 2026 6:28 AM - StreetInsider
Merck (MRK) PT Raised to $170 at BMO Capital
August 20, 2026 7:37 AM - StreetInsider
Moderna stock pulls back after massive one-day rally: analysts weigh in
August 20, 2026 7:23 AM - StreetInsider
Guggenheim Reiterates Buy Rating on Merck (MRK)
August 20, 2026 6:47 AM - StreetInsider
RBC Capital Downgrades Merck (MRK) to Sector Perform
August 20, 2026 5:04 AM - StreetInsider
Merck (MRK) call put ratio 3 calls to 1 put with a focus on 6K contracts of November 135 puts
August 20, 2026 4:50 AM - StreetInsider
UBS Downgrades Merck (MRK) to Neutral
August 20, 2026 2:49 AM - StreetInsider
Moderna (MRNA) PT Raised to $89 at Morgan Stanley
August 19, 2026 4:23 PM - StreetInsider
Morgan Stanley Upgrades Merck (MRK) to Overweight
August 19, 2026 4:22 PM - StreetInsider
Merck (MRK) call put ratio 3.1 calls to 1 put after INTerpath-001 trial results
August 19, 2026 11:22 AM - StreetInsider
Merck (MRK) call put ratio 1.4 calls to 1 put into INTerpath-001 trial results
August 19, 2026 9:17 AM - StreetInsider
William Blair Upgrades Moderna (MRNA) to Outperform, 'we believe Moderna has a clear line of sight to revenue diversification from the COVID business
August 19, 2026 8:11 AM - StreetInsider
Moderna shares soar on melanoma drug trial success
August 19, 2026 7:03 AM - StreetInsider
Merck and Moderna's melanoma drug combo beats Keytruda alone in trial
August 19, 2026 6:45 AM - StreetInsider
Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA® Met Endpoints of Recurrence-Free Survival (RFS) and Distant Metastasis-Free Survival (DMFS) in Patients Wi
August 19, 2026 6:45 AM - BizWire
Form 4 Merck & Co., Inc. For: Aug 13 Filed by: Guindo Chirfi
August 13, 2026 5:03 PM - SEC Filing
Form 144 Merck & Co., Inc. Filed by: Guindo Chirfi
August 13, 2026 4:17 PM - SEC Filing
Form 4 Merck & Co., Inc. For: Aug 12 Filed by: Zachary Jennifer
August 13, 2026 4:13 PM - SEC Filing
Form 144 Merck & Co., Inc. Filed by: DeLuca Richard R.
August 12, 2026 4:24 PM - SEC Filing
Form 144 Merck & Co., Inc. Filed by: Zachary Jennifer
August 12, 2026 4:19 PM - SEC Filing
Form 4 Merck & Co., Inc. For: Aug 10 Filed by: DeLuca Richard R.
August 12, 2026 4:11 PM - SEC Filing
Daiwa Securities Upgrades Merck (MRK) to Outperform (2)
August 12, 2026 4:30 AM - StreetInsider
Form 144 Merck & Co., Inc. Filed by: DeLuca Richard R.
August 11, 2026 4:15 PM - SEC Filing
Form 144 Merck & Co., Inc. Filed by: DeLuca Richard R.
August 11, 2026 10:27 AM - SEC Filing
Merck (MRK) PT Raised to $145 at Argus
August 11, 2026 7:12 AM - StreetInsider
Form 144 Merck & Co., Inc. Filed by: DeLuca Richard R.
August 10, 2026 4:43 PM - SEC Filing
Form 4 Merck & Co., Inc. For: Aug 06 Filed by: DeLuca Richard R.
August 10, 2026 4:28 PM - SEC Filing
Form 4 Merck & Co., Inc. For: Aug 05 Filed by: Maraldo David R.
August 7, 2026 4:22 PM - SEC Filing
Form 4 Merck & Co., Inc. For: Aug 05 Filed by: Williams David Michael
August 7, 2026 4:21 PM - SEC Filing
Form 4 Merck & Co., Inc. For: Aug 06 Filed by: Guindo Chirfi
August 7, 2026 4:19 PM - SEC Filing
Form 10-Q Merck & Co., Inc. For: Jun 30
August 7, 2026 4:13 PM - SEC Filing
Form 13F-HR Merck & Co., Inc. For: Jun 30
August 7, 2026 4:05 PM - SEC Filing
Form 144 Merck & Co., Inc. Filed by: Guindo Chirfi
August 6, 2026 4:47 PM - SEC Filing
Form 144 Merck & Co., Inc. Filed by: DeLuca Richard R.
August 6, 2026 4:45 PM - SEC Filing
Trump Administration Weighs Order On Autism And Vaccines - Bloomberg
August 6, 2026 4:36 PM - StreetInsider
FDA accepts Merck's sBLA for Enflonsia to cover second RSV season
August 6, 2026 6:45 AM - StreetInsider
U.S. FDA Accepts sBLA for ENFLONSIA™ (clesrovimab-cfor) to Update its Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease Indication to Include Children Under Two Years at Increased Ri
August 6, 2026 6:45 AM - BizWire
Form 144 Merck & Co., Inc. Filed by: Williams David Michael
August 5, 2026 4:29 PM - SEC Filing
Form 144 Merck & Co., Inc. Filed by: Maraldo David R.
August 5, 2026 4:29 PM - SEC Filing
Form 8-K Merck & Co., Inc. For: Aug 04
August 4, 2026 6:48 AM - SEC Filing
Merck shares rise on big Q2 earnings beat, adjusted FY outlook
August 4, 2026 6:47 AM - StreetInsider
Merck (MRK) Tops Q2 EPS by 14c, Beats on Revenue; Offers FY26 EPS Guidance
August 4, 2026 6:33 AM - StreetInsider
Merck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2026 Financial Results; Highlights Key Regulatory and Clinical Milestones Across Broad, Diverse Pipeline
August 4, 2026 6:30 AM - BizWire
Merck (MRK) call put ratio 1.2 calls to 1 put into quarter results
August 3, 2026 10:33 AM - StreetInsider
Merck (MRK) call put ratio 1.3 calls to 1 put into quarter results
August 3, 2026 6:05 AM - StreetInsider
U.S. biopharma earnings: Eli Lilly (LLY), Pfizer (PFE) take the stage
August 1, 2026 10:00 AM - StreetInsider
Merck (MRK) call put ratio 2 calls to 1 put into quarter results
July 31, 2026 11:02 AM - StreetInsider
Merck (MRK) Declares $0.85 Quarterly Dividend; 2.6% Yield
July 29, 2026 11:04 AM - StreetInsider
Merck Announces Fourth-Quarter 2026 Dividend
July 29, 2026 11:04 AM - BizWire
Merck (MRK) PT Raised to $150 at Barclays
July 29, 2026 5:20 AM - StreetInsider
Merck (MRK) PT Raised to $105 at Bernstein SocGen Group
July 27, 2026 9:29 AM - StreetInsider
Merck signs HIV prevention drug licenses covering 129 countries
July 24, 2026 6:45 AM - StreetInsider
Merck Announces Initial Access Plans for Alimatravir, an Investigational Once-Monthly Oral HIV Pre-Exposure Prophylaxis in Phase 3 Development
July 24, 2026 6:45 AM - BizWire
Tessera Therapeutics names former Merck executive as new CEO
July 23, 2026 1:00 PM - StreetInsider
Tessera Therapeutics Appoints Joseph Romanelli as President and Chief Executive Officer
July 23, 2026 1:00 PM - PR NewsWire
Gilead to present lenacapavir HIV trial data at AIDS 2026
July 21, 2026 10:00 AM - StreetInsider
Gilead and Merck HIV pill shows strong results in Phase 3 trials
July 21, 2026 10:00 AM - StreetInsider
Gilead to Present New HIV Research at AIDS 2026 Across Prevention, Treatment and Cure
July 21, 2026 10:00 AM - BizWire
Investigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapy
July 21, 2026 10:00 AM - BizWire
Phanes expands Merck collaboration to study cancer drug combination
July 21, 2026 6:13 AM - StreetInsider
Guggenheim Reiterates Buy Rating on Merck (MRK)
July 17, 2026 7:07 AM - StreetInsider
Personalis (PSNL) explores potential sale after interest from Merck and others - source
July 16, 2026 3:28 PM - StreetInsider
MilliporeSigma Announces Opening of BioReliance® Testing Facility in Darmstadt, Germany to Support Drug Product Release in Europe
July 16, 2026 8:11 AM - Globe NewsWire
FDA approves Merck's Lipfendra as first oral PCSK9 inhibitor
July 16, 2026 6:45 AM - StreetInsider
Merck’s LIPFENDRA® (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with Hypercholesterolemia
July 16, 2026 6:45 AM - BizWire
Guggenheim Reiterates Buy Rating on Merck (MRK)
July 16, 2026 6:39 AM - StreetInsider
Merck to present HIV pipeline data at AIDS 2026 conference
July 15, 2026 7:00 AM - StreetInsider
Merck to Present New Data on Daily, Weekly, and Monthly Options Across its HIV Treatment and Prevention Pipeline at AIDS 2026
July 15, 2026 7:00 AM - BizWire
Merck's Keytruda meets PFS endpoint in endometrial cancer trial
July 15, 2026 6:45 AM - StreetInsider
KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR)
July 15, 2026 6:45 AM - BizWire
Merck (MRK) PT Raised to $140 at JPMorgan
July 13, 2026 8:47 AM - StreetInsider
Merck (MRK) PT Raised to $142 at BMO Capital
July 13, 2026 7:34 AM - StreetInsider
Merck (MRK) PT Raised to $145 at Guggenheim
July 13, 2026 6:51 AM - StreetInsider
FDA clears Merck's Keytruda combo for muscle-invasive bladder cancer
July 10, 2026 2:10 PM - StreetInsider
FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Ad
July 10, 2026 2:10 PM - BizWire
FDA grants breakthrough designation to EMD Serono's lupus drug enpatoran
July 8, 2026 8:00 AM - StreetInsider
EMD Serono Announces FDA Breakthrough Therapy Designation for Enpatoran in Lupus Patients with Active Skin Manifestations
July 8, 2026 8:00 AM - BizWire
Merck (MRK) PT Raised to $150 at Wells Fargo
July 8, 2026 6:29 AM - StreetInsider
Merck (MRK) PT Raised to $113 at Morgan Stanley
July 8, 2026 6:08 AM - StreetInsider
Merck (MRK) PT Raised to $150 at HSBC
July 6, 2026 1:35 AM - StreetInsider
Form 4 Merck & Co., Inc. For: Jun 30 Filed by: Seidman Christine E
July 1, 2026 8:47 AM - SEC Filing
Form 4 Merck & Co., Inc. For: Jun 30 Filed by: Karsanbhai Surendralal Lanca
July 1, 2026 8:45 AM - SEC Filing
Form 4 Merck & Co., Inc. For: Jun 30 Filed by: Coe Mary Ellen
July 1, 2026 8:42 AM - SEC Filing
Merck to Hold Second-Quarter 2026 Sales and Earnings Conference Call Aug. 4
July 1, 2026 6:45 AM - BizWire
Merck (MRK) PT Raised to $155 at Scotiabank
June 30, 2026 7:16 AM - StreetInsider
U.S. House committee opens investigation into Merck, AbbVie China drug trials - Reuters
June 30, 2026 6:02 AM - StreetInsider
Merck (MRK) PT Raised to $141 at BofA Securities
June 30, 2026 5:23 AM - StreetInsider
Merck reaches deal to expand HIV drug access via ADAP programs
June 29, 2026 6:45 AM - StreetInsider
Merck Announces New Agreement with ADAP Crisis Task Force to Improve Access and Care for People Living with HIV
June 29, 2026 6:45 AM - BizWire
FDA approves Merck's Keytruda combo with Trodelvy for TNBC
June 25, 2026 6:45 AM - StreetInsider
FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each with Trodelvy® (sacituzumab govitecan-hziy) as First-Line Treatment of PD-L1+ (CPS �
June 25, 2026 6:45 AM - BizWire
Form 11-K Merck & Co., Inc. For: Dec 31
June 24, 2026 3:12 PM - SEC Filing
Form 11-K Merck & Co., Inc. For: Dec 31
June 24, 2026 3:09 PM - SEC Filing
Form 11-K Merck & Co., Inc. For: Dec 31
June 24, 2026 3:05 PM - SEC Filing
The Quest to Repair What Multiple Sclerosis Takes Away
June 24, 2026 8:30 AM - StreetInsider
Next-Generation DNA Repair Inhibitors Could Capture Billions in Emerging Market
June 24, 2026 8:30 AM - StreetInsider
EMD Serono names new global commercial head and North America president
June 24, 2026 8:15 AM - StreetInsider
EMD Serono Announces Healthcare Leadership Changes for Global Commercial Strategy and North America
June 24, 2026 8:15 AM - BizWire
EU approves Merck's Keytruda plus Padcev for bladder cancer
June 24, 2026 6:45 AM - StreetInsider
European Commission Approves KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First PD-1 Inhibitor Plus Antibody-Drug Conjugate Regimen for Adults With Cisplatin-Ineligible Resect
June 24, 2026 6:45 AM - BizWire
CICC Starts Merck (MRK) at Outperform
June 24, 2026 5:45 AM - StreetInsider
Merck KGaA, Darmstadt, Germany, Collaborates with Versant Ventures to Launch Saturnus Bio to Advance Treatments for Rare Genetic Cardiomyopathies
June 23, 2026 9:30 AM - BizWire
Merck's tulisokibart meets Phase 3 endpoints in ulcerative colitis trial
June 22, 2026 6:45 AM - StreetInsider
Merck’s Tulisokibart Met Primary and Key Secondary Endpoints in the Phase 3 ATLAS-UC Induction-only Study in Patients With Moderately to Severely Active Ulcerative Colitis (UC)
June 22, 2026 6:45 AM - BizWire
FDA approves Merck's Capvaxive for children at higher pneumonia risk
June 18, 2026 6:45 AM - StreetInsider
U.S. FDA Approves an Additional Indication for CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) in Children and Adolescents Aged 2 through 17 at Increased Risk for Pneumococcal Disease
June 18, 2026 6:45 AM - BizWire
Johnson & Johnson to stay out of obesity drugs, focus on cancer, CEO says
June 17, 2026 11:15 AM - StreetInsider
Study Reveals Dog Owners and Veterinarians See Challenges in Treating Allergic Skin Disease, Highlighting a Need for a Targeted Rapid Onset Treatment for Dogs of All Ages
June 17, 2026 6:45 AM - BizWire
Full Article List
